Background and objective: Malignant airway obstruction (MAO), a common complication of patients with advanced lung cancer, causes debilitating dyspnoea and poor quality of life. Two common interventions used in the treatment of MAO include bronchoscopy with airway stenting and external beam radiotherapy (EBRT). Data are limited regarding their clinical effectiveness and overall effect on survival. Methods: A retrospective chart review of patients treated with airway stenting and/or EBRT at the Johns Hopkins Hospital for MAO between July 2010 and January 2017 was reviewed. Demographics, performance status, cancer histology, therapeutic intervention and date of death were recorded. Survival was calculated using cox regression analysis. Results: Of the 606 patients who were treated for MAO, 237 were identified as having MAO and included in the study. Sixty-eight patients underwent rigid bronchoscopy and stenting, 102 EBRT and 67 a combined approach. Patients who underwent stenting hand an increased hazard ratio (HR) of death in comparison to those who received combination therapy (HR: 2.12, 95% CI: 1.02, 4.39), while there was a trend towards significance in the EBRT alone group in comparison to the combination therapy group (HR: 1.62, 95% CI: 0.93, 2.83). Conclusion: In this retrospective analysis, combination therapy with stenting and EBRT led to better survival in comparison to stenting or EBRT alone. Prospective cohort trials are needed to confirm these results.
INTRODUCTION
Malignant airway obstruction (MAO) occurs in approximately 30% of all patients with advanced stage lung cancer 1 and can lead to debilitating dyspnoea, cough and haemoptysis. These symptoms significantly impair quality of life. 2 Once MAO is diagnosed, the average survival can be as low as 1-2 months if left untreated. 3 The three main treatment modalities used for the symptomatic relief of MAO are external beam radiotherapy (EBRT), rigid bronchoscopy with tumour excision/destruction, dilation and airway stent placement and combination therapy using both of these interventions. These modalities have not been compared and there is currently no gold standard. Little data exist on their efficacy and effectiveness. In a retrospective analysis of 50 patients, airway stenting was shown to increase survival in patients with intermediate performance status in comparison to poor performance, with an overall median survival of 117 days. 4 Another retrospective review of 65 patients showed an average median survival of 6.2 months post-stenting. 5 In a retrospective review of 43 patients who received both
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Malignant airway obstruction is a complication for lung cancer patients. Multiple modalities exist for the treatment of this ailment, including airway stenting and external beam radiotherapy (EBRT). We showed retrospectively that airway stenting combined with EBRT was associated with increased survival in comparison to either treatment in isolation.
stenting and EBRT, the overall survival was shown to be 3.44 months. 6 There was a significant difference in the survival of stented patients who received full course therapy in comparison to patients who had to have EBRT stopped early (8.4 months vs 21 days, respectively). 6 Additionally, the direct impact of these treatments on survival is poorly understood, 7 and there has not been a comparison of treatment modalities at a single centre. This retrospective study focuses on a single-centre clinical experience with MAO treatment using rigid bronchoscopy with airway stenting and radiotherapy.
METHODS
This was a retrospective chart review study conducted at The Johns Hopkins Hospital from July 2010 to January 2017. Approval was obtained from the Johns Hopkins University institutional review board (IRB#: NA_00081563) prior to initiation of data collection. Current Procedural Terminology (CPT) codes: 31631 (tracheal stent), 31636 (bronchial stent) 31637 (additional bronchial stent) and 77401-77416 (EBRT) were used to identify patients who had undergone palliative bronchoscopy with airway stenting or EBRT for MAO during the predefined dates. Charts were reviewed to exclude patients who had an intervention for nonmalignant disease. All patients with MAO were reviewed by a multidisciplinary tumour board, represented by medical oncology, radiation oncology, interventional pulmonology and thoracic surgery. Patients subsequently underwent the procedure that by the board was felt to be most beneficial for the patient.
Demographic information, including age, gender, race and income, was collected via chart review. Additional information such as smoking history (current/ former smoker vs non-smoker), chemotherapy regimen, level of obstruction, degree of obstruction and Eastern Cooperative Oncology Group (ECOG) performance status score at the time of diagnosis were also collected if available. The level of obstruction and degree of obstruction were estimated via bronchoscopy or computed tomography (CT) scan measurements. The patient's cancer stage and histology including subtype for non-small cell lung cancer were noted. Type of therapeutic intervention and date and the order they received the interventions in the EBRT/stent combination group were recorded, with dual treatment within 30 days considered treatment at the same time. Dates of death were recorded from the chart and verified using the social security death index (SSDI) and via medical records.
Statistical analysis
Baseline characteristics were compared among the three treatment modalities using multiple methods. For continuous variables, linear regression was used to determine whether there was a difference between interventions. For dichotomous variables, logistic regression was applied. With categorical variables, multinomial logistic regression was conducted to detect a difference. To determine a difference in means between the three intervention groups, analysis of variance was conducted. When a statistically significant difference was found, simple t-test or tests of proportions were used to investigate differences between two groups at a time. Missing data were assumed to be at random.
For survival analysis, median survival by treatment type based on the time of intervention to the date of death or a predetermined administrative censor date of 1 July 2017 were calculated using the method of Kaplan-Meier. The log-rank test was used to detect differences in the probability of survival between the three treatment arms. Univariate cox proportional hazard analysis was conducted to determine risk factors associated with increased or decreased mortality. Multivariate Cox proportional hazard analysis was performed using variables that were associated with increased or decreased mortality on univariate analysis, or determined to be clinically meaningful. Proportional hazard assumption testing was performed by examination of Schoenfeld residuals. All statistical analyses were performed using STATA IC, version 14.2 (Stata Corp., College Station, TX, USA).
RESULTS
A total of 606 patients with MAO were identified. Those with non-MAO (NMAO) were excluded. The remaining 237 (39%) had MAO and were included in the final analysis ( Fig. 1 ). Sixty-eight (28.7%) were treated with rigid bronchoscopy with tumour excision/destruction and stenting, 102 (43%) were treated with EBRT alone and 67 (28.3%) patients received both therapies. The baseline characteristics of the patients in the three treatment arms are shown in Table 1 . Of the patients who received both interventions, 72% received them at the same time and there was no significant difference between those who received stenting or EBRT first (P = 0.644).
Among the three intervention groups, the median time of death in the stent only, EBRT only and combination groups was 113.5, 84.5 and 157 days, respectively. The overall mortality between the three groups was not significantly different. Patients in the stent group had a mortality rate of 63.2%, the EBRT group had 65.7% and the combined group had a mortality of 68.6%.
The Kaplan-Meier curve is shown in Figure 2 . When conducting Cox proportional hazard modelling, there was no violation of proportional hazards. Interactions were tested between smoking and malignancy, and intervention and ECOG, with no significant interaction identified. After adjusting for age, race, ECOG score, chemotherapy, degree of obstruction and type of malignancy, the use of stenting had an increased hazard of death in comparison to combination therapy (hazard ratio (HR) = 2.12, 95% CI: 1.02, 4.39) ( Table 2 ). There was a trend towards increased hazard of death for the EBRT only group in comparison to the combination therapy group (HR = 1.62, 95% CI: 0.93, 2.893). There was no association with increased hazard of death by malignancy type, smoking status, age, race or female sex. ECOG scores of 2 and 3 were also associated with a statistically significant increased hazard of death. There was no association between HR and degree of obstruction or location of obstruction. There was an increased HR of death for those who received 1.5 2 0 † EBRT versus stent and EBRT versus both (P < 0.001). ‡ Stent versus EBRT (P = 0.007). § Stent versus EBRT (P = 0.007). ¶ SCLC: stent versus EBRT (P = 0.006). 'Other' cancers: stent versus EBRT (P < 0.001) and EBRT versus both (P = 0.002). † † Trachea: EBRT versus stent (P < 0.001) and EBRT versus both groups (P < 0.001). Right main stem: EBRT versus stent (P = 0.02) and EBRT versus both (P < 0.001). Left main stem: stent versus EBRT group (P = 0.01). Right upper lobe: EBRT versus stent (P < 0.01) and EBRT versus both (P < 0.01). Right middle lobe: EBRT versus stent (P < 0.01) and EBRT versus both (P < 0.01). Right lower lobe: EBRT versus stent (P = 0.02) and EBRT versus both (P = 0.02). Left upper lobe: EBRT versus stent (P = 0.03) and EBRT versus both (P < 0.01). ‡ ‡ EBRT versus both for complete obstruction (P = 0.012). Stent versus EBRT for severe obstruction (P = 0.049). Stent versus EBRT and EBRT versus both for moderate obstruction (P = 0.0005 and P = 0.0008, respectively).
EBRT, external beam radiotherapy; ECOG, Eastern Cooperative Oncology Group.
combination therapy at the same time, in comparison to those who received therapies further apart in a univariate Cox model analysis (HR = 3.39, 95% CI: 1.68, 6.87) which continued to be significant in the adjusted model (HR = 4.46, 95% CI: 1.05, 18.98). There was no association with level of obstruction (in comparison to tracheal obstruction), or with the severity of obstruction and hazard of death (P = 0.24 and P = 0.69, respectively).
DISCUSSION
MAO is a common complication in patients with advanced stage lung cancer as well as those with metastatic non-lung primaries, that leads to decreased quality of life and ultimately to death, usually within 1-2 months if left untreated. 3 Although three major interventions, bronchoscopy with airway stenting, EBRT and combination stenting with EBRT, are used to treat MAO, there is a paucity of comparative survival data between them. Currently, no prospective, randomized data exist, and thus our retrospective analysis adds significantly to the field. Although survival in all arms of the study was poor, we found that combination therapy of EBRT with stenting was associated with better survival as compared to EBRT or stenting alone. There was also no difference between EBRT and stenting as a single therapy. We believe that the most meaningful clinical risk factors addressed in this study included location of obstruction, degree of obstruction, ECOG score and presence of concomitant chemotherapy. Interestingly, after adjustment, there did not appear to be a survival difference for any of the factors described above other than ECOG. This is reassuring, as elevated ECOG scores have been well known to be associated with worse survival. 8 There was also an association between receiving chemotherapy and decreased hazard of death, another expected finding to further substantiate our findings.
We postulate that the reason patients undergoing rigid bronchoscopy with airway stenting in combination with EBRT had better survival due to the immediate relief of the mechanical obstruction provided by bronchoscopy and the lasting effects of radiation. Immediate, that is within minutes, relief compared to days to weeks needed for EBRT to take effect may prevent other downstream effects of continued obstruction, such as haemoptysis, atelectasis, and postobstructive pneumonia. Palliative EBRT is generally given as 3 Gy per fraction up to a total of 30 Gy therapy 9 and takes up to 2 weeks to deliver the total dose. Clearly, the goal of EBRT is not only to treat the endobronchial obstruction, but also to definitively treat the cause of the obstruction. EBRT and endobronchial stenting have their unique side effect profiles, with pneumonitis being associated with EBRT and migration and granulation tissue formation associated with airway stent placement. EBRT may also treat more distal airways where bronchoscopic therapies and airway stenting may not be feasible.
Although our results are intriguing, there are several limitations that suggest a large, multicentre trial should be conducted. The retrospective single centre nature of the study limited us to the data available in the chart. Additionally, patient selection and referral bias were not able to be fully controlled for; however, at our centre, all patients were reviewed by a multidisciplinary tumour board represented by medical oncology, radiation oncology, interventional pulmonology and thoracic surgery. In this discussion, all potential therapeutic options are openly discussed and a consensus agreement results in procedural selection chosen based on what is perceived as the safest and most effective procedure for these patients at that time. As EBRT does not require sedation or anaesthesia with its associated risks, sicker patients with MAO and higher American Society of Anesthesia (ASA) scores may have been sent for EBRT. This self-selection of sicker patients for EBRT may provide an alternative explanation for the difference in median time to death in this group compared with the stenting and combination groups. However, the results were still significant when adjusting for the proportion of patients in the study where ECOG score was recorded (58% of the patients). All treatment modalities were done in a tertiary care centre, which limits the generalizability of the study. And perhaps the most important limiting factor is the lack of randomization. Given the retrospective nature of this study, it was not possible for us to randomize patients to one of the three arms.
Our study examined patients who underwent both modalities for MAO with a significant survival advantage found as compared with stenting or EBRT alone. Although the majority of patients received both treatments at the same time, those who received stenting first did not differ in survival in comparison to those who received EBRT first. Interestingly, those who received both therapies within 30 days of one another did have a trend towards worse outcomes. Given the circumstances, these patients likely had more severe disease than the cohorts that received one therapy at a time. Survival in patients with MAO, where bronchoscopy has failed to re-cannulate the airway, has been shown to be worse in a prospective study, 10 possibly introducing another element of bias. Another limitation is that we were only able to focus on survival and not on health-related quality of life. 11 Given that the lives of these patients are limited, being symptom-free is of the utmost importance, but the retrospective study design prevented this analysis; however, this is an important factor to investigate in prospective studies.
In conclusion, MAO can cause significant distress, anxiety, dyspnoea, cough and pain. Three major treatment modalities, bronchoscopy with airway stenting, EBRT and combination stenting with EBRT, were examined in a retrospective fashion by which combination therapy demonstrated better survival outcomes. We believe that the use of combination airway stenting and EBRT therapy is warranted in this patient population, as it shows a survival benefit. Prospective randomized trials would be beneficial to further investigate this, but unfortunately it would be difficult to perform without excluding patients who present with severe dyspnoea, given their need for immediate bronchoscopic intervention. It is possible, however, that a randomized trial could be designed for all other patients who present with findings of MAO.
